Revenue has steadily increased from $482 million in 2023 to an estimated $764 million in 2025, reflecting strong sales growth. Gross profit margins have improved significantly, hitting 72% gross margin in Q2 2026, a notable uplift from closer to 64% in 2023. However, operating income and net income remain negative overall, though recent quarters have shown a path toward profitability with margin expansion and modest positive EPS reported in the last two quarters.

Revenue growth is driven by increased product adoption and market penetration in innovative spine technologies. Growth is consistent and shows a solid upward trajectory quarter-over-quarter, supported by higher sales volumes and improved pricing power.

Gross margins have improved from about 64% in 2023 to above 70% in mid-2026, indicating better cost controls and high-value product mix. Operating margins remain negative due to elevated SG&A expenses which consistently account for over 60% of revenue, but the EBITDA margin turned positive recently reaching 3.0% in Q2 2026, signaling operational leverage is starting to materialize.

Recent earnings quality shows a marked improvement with positive EPS of $0.07 in Q2 2026 against expectations, driven by revenue growth and margin expansion. The net income losses in prior years were impacted by high operating expenses and one-time charges, but the shift toward positive EBITDA and net income stabilization suggests improving sustainable profitability.

Annual revenue growth accelerated from 2023's $482 million to $764 million in 2025, representing approximately a 58.5% increase over two years. Q2 2026 revenue of $213.5 million marks a QoQ increase of roughly 11.1% from Q1 2026.

EPS showed substantial negative values from 2023 to early 2025, with losses over -$1.00 per share annually. However, in 2026, EPS turned positive for two consecutive quarters at $0.06 and $0.07 respectively, indicating a strong earnings growth reversal trend.

Growth is mainly driven by expanded market share in spine implant technologies, increased product adoption, and continuous innovation backed by focused R&D expenditures averaging $18–23 million per quarter. The company also benefits from scaling its operations and increasing surgical procedure volumes.

Growth appears largely organic, fueled by existing product lines with incremental innovation. Research and development investments support product pipeline sustainability, but elevated SG&A expenditures call for monitoring to ensure growth translates into long-term profitability.

Gross margins improved from approximately 64% in 2023 to over 72% in recent quarters, highlighting better cost efficiencies. Operating margins, though negative, have narrowed from -22% in 2023 to less than -1% in Q2 2026. EBITDA margin turned positive recently at 3.0%. Net margin remains negative but is improving from nearly -39% in 2023 to about -12% in mid-2026.

While detailed ROE and ROA metrics are unavailable, improving net income figures and margin expansions imply progress towards positive returns on equity and assets as losses decrease and operating efficiency gains persist.

Gross margin improvement appears sustainable due to durable product mix and fixed cost leverage. Yet, sustaining positive operating and net margins depends on continued SG&A expense control and translating revenue growth into operating leverage to reduce losses further.